A separate cross-sectional study demonstrated that IgA anti-MAA antibody improved the 10-year prediction of coronary atherosclerosis in RA patients, above and beyond predictions afforded by a standard cardiovascular risk calculation (C-statistic 0.761 with IgA anti-MAA vs.0.733 without IgA anti-MAA) (36). This evidence concerns the gene CD79A and coronary atherosclerosis.